Tetraphase Pharmaceuticals, Inc. (TTPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
TTPH Stock Summary
- With a year-over-year growth in debt of -92.22%, Tetraphase Pharmaceuticals Inc's debt growth rate surpasses merely 1.81% of about US stocks.
- Revenue growth over the past 12 months for Tetraphase Pharmaceuticals Inc comes in at -57.03%, a number that bests only 2.98% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TTPH comes in at 146.09% -- higher than that of 97.54% of stocks in our set.
- Stocks that are quantitatively similar to TTPH, based on their financial statements, market capitalization, and price volatility, are BIOC, APDN, DDD, MBII, and SCWX.
- Visit TTPH's SEC page to see the company's official filings. To visit the company's web site, go to www.tphase.com.
TTPH Stock Price Chart Interactive Chart >
TTPH Price/Volume Stats
|Current price||$2.20||52-week high||$8.60|
|Prev. close||$2.28||52-week low||$0.56|
|Day high||$2.27||Avg. volume||932,542|
|50-day MA||$2.42||Dividend yield||N/A|
|200-day MA||$2.32||Market Cap||15.98M|
Tetraphase Pharmaceuticals, Inc. (TTPH) Company Bio
Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create antibiotics for serious and life-threatening MDR bacterial infections. The company was founded in 2006 and is based in Watertown, Massachusetts.
TTPH Latest News Stream
|Loading, please wait...|
TTPH Latest Social Stream
View Full TTPH Social Stream
Latest TTPH News From Around the Web
Below are the latest news stories about Tetraphase Pharmaceuticals Inc that investors may wish to consider to help them evaluate TTPH as an investment opportunity.
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) (announced new clinical program focused on the development of NurOwn as a treatment for Alzheimer's disease) * Burning Rock Biotech Ltd (NASDAQ: BNR) (went public June 12) * Cardiff Oncology Inc (NASDAQ: CRDF) * ESSA Pharma Inc (NASDAQ: EPIX) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Horizon Therapeutics PLC (NASDAQ: HZNP) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Kamada Ltd. (NASDAQ: KMDA) * Novavax, Inc. (NASDAQ: NVAX) * Passage Bio Inc...
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value…
The bidding competition for Tetraphase Pharmaceuticals (TTPH) is not over yet. La Jolla Pharmaceutical (LJPC) has submitted an unsolicited bid of $43.0M in cash plus an additional $16.0 payable under contingent value rights (CVRs).The board has determined that the offer is superior to Melinta Therapeutics' (MLNT) bid of $39.0M in...
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) seems to be far from over. What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, potentially payable under contingent value rights issued in the transaction. Tetraphase markets Xerava, an antibiotic for treating complicated intra-abdominal infections. After Tetraphase signed an agreement to be acquired by AcelRx Pharmaceuticals … Full story available on Benzinga.com
Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today announced that on June 19, 2020, its Board of Directors received an unsolicited proposal from La Jolla Pharmaceutical Company ("La Jolla") to acquire Tetraphase for $43.0 million in cash, plus an additional aggregate amount of $16.0 million in cash potentially payable under contingent value rights ("CVRs") to be issued in the transaction (the "La Jolla Proposal"), and that on June 21, 2020 the Board determined that the La Jolla Proposal is a "Superior Offer" under the terms of the Agreement and Plan of Merger, dated June 4, 2020, t...
TTPH Price Returns
Continue Researching TTPHHere are a few links from around the web to help you further your research on Tetraphase Pharmaceuticals Inc's stock as an investment opportunity:
Tetraphase Pharmaceuticals Inc (TTPH) Stock Price | Nasdaq
Tetraphase Pharmaceuticals Inc (TTPH) Stock Quote, History and News - Yahoo Finance
Tetraphase Pharmaceuticals Inc (TTPH) Stock Price and Basic Information | MarketWatch